Shionogi Files Antiviral NDA In China, Eyes Wider Use

Competes with Pfizer's Paxlovid Upon Approval

Undeterred by recent home turf setback, Japanese drug maker Shionogi rides a China’s policy tailwind and bets on Chinese approval for its antiviral COVID drug.

Doctor with Covid pill
SHIONOGI FILES CHINA NDA FOR ITS COVID PILL, EYES WIDER USE • Source: Shutterstock

Days after a surprise setback from its home country regulators, Shionogi & Co. Ltd.hopes a Chinese approval for its antiviral will help the Japanese drug maker in the second largest pharma market.

Partnered with Ping An, China’s major life insurance company, Shionogi has filed a new drug approval application with the China...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip